Board recommended final dividend for FY26
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported strong FY26 results with standalone revenue from operations growing 16.1% to ₹1,06,049 Lacs from ₹91,326 Lacs in FY25. Net profit after tax increased 23.9% to ₹10,344 Lacs from ₹8,346 Lacs, with EPS rising to ₹6.55 from ₹5.42. The Board recommended a final dividend of ₹0.45 per equity share (45% on face value of ₹1) for FY26, subject to shareholder approval at the AGM. Statutory auditors T R Chadha & Co LLP issued an unmodified opinion on both standalone and consolidated financial results. Key board decisions included appointment of two new Independent Directors and re-appointment of statutory auditors for a second 5-year term.
The company delivered robust profit growth of ~24% YoY with strong cash generation from operations at ₹12,882 Lacs. The recommended dividend signals confidence in financial health, though the absolute amount is modest at ₹0.45 per share.